Evidence map›Paper›PMID 28798515›Full record

ReviewAustralian prescriber2017

Genomic testing as a tool to optimise drug therapy.

Andrew A Somogyi, Elizabeth Phillips

Abstract readReview
In one paragraph

Review in Australian prescriber, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Pharmacogenomics in the era of personalised medicine.The Medical journal of Australia · 2022
    Article
  5. Article
  6. Article
  7. Pharmacogenomics and drug therapy.Australian prescriber · 2018
    Article
  8. Drugs and genetics.Australian prescriber · 2017
    Article
  9. Retail genetics.Australian prescriber · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Andrew A SomogyiClinical and Experimental Pharmacology, Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide.
Elizabeth PhillipsCentre for Clinical Pharmacology and Infectious Diseases, Institute for Immunology and Infectious Diseases, Murdoch University, Perth.

Funding

Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Stephany Norah Duda · 2015 to 2026
$27.5M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0M
The Structural and Functional Basis of HLA-associated Drug HypersensitivityR01AI103348 · NIAID · UNIVERSITY OF FLORIDA · PI OSTROV, DAVID A · 2013 to 2016
$1.5M
NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI103348NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

abacaviradverse drug reactionallopurinolazathioprinecarbamazepinepharmacogenomicsphenytoin

Identifiers

PMID28798515
PMCPMC5478394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.